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The S130K fibroblast growth factor–1
mutant induces heparin-independent
proliferation and is resistant to thrombin
degradation in fibrin glue
Paula K. Shireman, MD, Lian Xue, MD, PhD, Ewa Maddox, Wilson H.
Burgess, PhD, and Howard P. Greisler, MD, Maywood and Hines, Ill; San
Antonio, Tex; and Rockville, Md 
Objective: Site-directed mutagenesis is an important technique that can alter cytokine
function, thereby eliciting desired responses. S130K is a mutation of fibroblast growth
factor–1 (FGF-1), with lysine replacing serine in the heparin-binding site. We measured
molecular stability and mitogenic activity of FGF-1 and S130K, both in the media and
when suspended in fibrin glue (FG), on smooth muscle cells (SMCs) and endothelial
cells (ECs) to determine if the mutation altered the function and potential clinical
applicability.
Methods: EC and SMC proliferation of soluble FGF-1 or S130K at 0, 0.1, 1, 10, or 100
ng/mL with heparin at 0, 5, 50, or 500 units (U)/mL was measured on growth-arrest-
ed cells in serum-free media. EC and SMC proliferation assays with cells on FG con-
taining either FGF-1 or S130K at 0, 1, 10, 100, or 1000 ng/mL in combination with
heparin at 0, 5, 50 or 500 U/mL were also performed during the exponential growth
phase. Molecular degradation by thrombin was measured by sodium dodecylsulfate-
polyacrylamide gel electrophoresis.
Results: S130K induces greater EC and SMC proliferation in the absence of heparin than
FGF-1 does (P <.0001 for both the 10 and 100 ng/mL doses). S130K is also signifi-
cantly more potent than FGF-1 in the presence of heparin. Heparin in the media
enhances cytokine-induced SMC and EC proliferation at doses of 5 U/mL, but inhibits
SMC proliferation at concentrations of 500 U/mL. For the FG data, unlike FGF-1,
S130K induces EC and SMC proliferation in the absence of heparin. The addition of 5
U/mL of heparin enhances the proliferation induced by S130K. For ECs, as the heparin
dose increases to 50 U/mL, proliferation decreases, as compared with the 5 U/mL con-
centration when either FGF-1 or S130K in the FG was compared at concentrations of
10, 100, and 1000 ng/mL (P <.01). S130K is more potent in FG than is FGF-1 both
with and without heparin and exhibits maximal EC and SMC proliferation at 10
ng/mL, whereas FGF-1 activity is maximal at 100 ng/mL. Gel electrophoresis demon-
strated that S130K was relatively more resistant to thrombin degradation than FGF-1.
Conclusions: Site-directed mutagenesis changed the potency and the heparin dependency
on cellular proliferation of FGF-1 in vitro. These techniques should allow the delivery
of mutant growth factors to areas of vascular intervention to induce specific, desired
responses. We believe that these studies will enhance our knowledge of the function of
various regions of the FGF-1 molecule, allowing us to more precisely design increasing-
ly more useful FGF-1 mutants. (J Vasc Surg 2000;31:382-90.)
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Site-directed mutagenesis is an important tech-
nique that allows specific amino acids to be altered
in a molecule. This provides opportunities to study
structure/function relationships and the relative
contribution of specific regions to the overall func-
tion of the molecule. In addition, changing specific
amino acids may allow the design of cytokines with
more useful functions than the wild-type molecule.
Workers in our laboratory have extensively studied
the effects of fibroblast growth factor–1 (FGF-1),
also known as acidic FGF, on smooth muscle cell
(SMC) and endothelial cell (EC) proliferation. We
have used fibrin glue (FG) as an extended delivery
system for FGF-1 on vascular grafts and angio-
plasty sites. Cytokines and heparin can be mixed
with fibrinogen before the addition of thrombin.
Thrombin cleaves the fibrinogen into fibrin, and a
matrix is created that contains the cytokines and
heparin. The body’s fibrinolytic system slowly
degrades the matrix, presumably releasing the
cytokines. FGF-1 was chosen for its strong chemo-
attractant and mitogenic activity for ECs, whereas in
the absence of heparin, FGF-1 induces minimal
SMC proliferation. With the addition of small
amounts of heparin, SMC proliferation in response
to FGF-1 dramatically increases. However, the addi-
tion of heparin is necessary in FG to protect FGF-1
from thrombin cleavage.
The synergism of FGF-1 and heparin is variable
on different cell lines. In the absence of heparin,
FGF-1 has about 1% or less of the proliferative activ-
ity on human umbilical vein endothelial cells as it
does in the presence of heparin.1 Other cell lines,
such as bovine aortic EC,2 mouse lung capillary
EC,2 and BALB/c 3T3 fibroblasts3 exhibit FGF-
1–induced mitogenic activity in the absence of
heparin. In addition, FGF-1 stimulates bovine aortic
ECs, but the mitogenic effect is augmented by the
addition of heparin.4
The interactions of heparin and FGF-1 are com-
plex and at this time, poorly understood. Heparin,
or heparin-like molecules, facilitate the binding of
FGF-1 to the transmembrane FGF receptor. The
FGF receptors are protein tyrosine kinases that are
activated by oligomerization.5 FGF-1 molecules
complex with the sugars on the polysaccharide
chains of heparin. Currently, heparin is believed to
form a biologically active dimer of FGF-1 that mod-
ulates the signaling through the FGF receptors.6
Our group has previously reported an FG system
containing FGF-1 and heparin used on grafts
implanted into the aortoiliac and thoracoabdominal
aortic positions in dogs.7,8 FG containing FGF-1
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and heparin placed onto expanded polytetrafluo-
roethylene grafts demonstrated complete endothe-
lial coverage at 4 weeks, which was never seen in the
control grafts. However, the inner capsule thickness
was also greater in the grafts treated with FGF-1 as
compared with the controls. FGF-1 stimulates both
EC and SMC proliferation and thereby may cause
intimal hyperplasia. An optimized FG would theo-
retically maximize EC proliferation while minimiz-
ing SMC proliferation that may lead to intimal
hyperplasia. Concern over intimal hyperplasia in the
canine grafts receiving FGF-1 and FG led us to spec-
ulate that the functions of the FGF-1 molecule
could be changed by site-directed mutagenesis to
induce either more EC compared with SMC prolif-
eration, or more angiogenic activity when compared
with wild-type FGF-1. Molecular stability may also
be enhanced, thus allowing the use of the altered
molecule within FG in the absence of heparin.
S130K is a mutant of FGF-1 that has a lysine at posi-
tion 130 instead of a serine. Residues 122-137 of
human FGF-1 constitute a major heparin-binding
domain in the protein.9 By changing the heparin-
binding characteristics of FGF-1, we hoped to alter
the functions of the molecule. The purpose of this
paper is to directly compare the activity of FGF-1
versus S130K on EC and SMC proliferation with the
cytokines contained within the media and within
FG, and the stability of the proteins to thrombin-
induced degradation.
METHODS
Animal care complied with The Guide for the
Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council, 1996) and the
“Principles of Laboratory Animal Care” (National
Institutes of Health publication no. 85-23, revised
1985). 
Construction of mutant FGF-1 prokaryotic
expression plasmids. Full-length (β) FGF-1 com-
plementary DNA was a gift of Dr Mike Jaye
(RhonePoulenc Rorer Central Research). The
pMJ17 plasmid containing FGF-1 was digested
with EcoRI and Hind III to generate a 1000–base
pair fragment with the EcoRI site at the 5’ end. β
FGF-1 was amplified from the complementary
DNA with the following primers: 5’ β AATTC-
C A T A T G G C T G A A G G G A A A T C A -
CC and 3’ UTR GATCAGATCTAAGTTGCTTA-
CAAATTCAGGCTC.
The mutant was then generated with the follow-
ing two consecutive polymerase chain reactions
(PCRs). The first PCR incorporates the mutagenic
primer CTCAAGAAGAATGGGAAGTGCAAACGC
GGTCC, 3’ UTR primer and β template (from
above) and is amplified with Vent DNA Polymerase
(New England Biolabs, Beverly, Mass). The mutant
fragment is then gel purified and used in the second
PCR. The second PCR incorporates the 5’ β primer,
the 3’ mutant fragment, and the β template and is
amplified with Taq Polymerase (Boehringer
Mannheim Corporation, Indianapolis, Ind). The
PCR product from the second reaction is then ligat-
ed into pBluescript and transformed into XL-1 Blue
competent cells. Plasmid DNA purified from indi-
vidual colonies were manually sequenced by the
dideoxy chain termination method using a
Sequenase 2.0 kit (US Biochemicals Corporation,
Cleveland, Ohio) and [35S]dATP (1000 Ci/mmol,
Amersham Corporation, Arlington Heights, Ill) to
verify mutation. The mutant was then digested out
of pBluescript with Nde I and Bgl II and direction-
ally ligated into the Pet3C expression vector.
Production of wild-type and mutant recombi-
nant FGF-1 and subsequent purification were per-
formed as described.9
Endothelial and SMC harvest. Adult, mongrel
dogs were anesthetized with thiopental sodium
(Abbott Laboratories, Morris Plains, NJ), intubated,
and ventilated. Anesthesia was maintained with
nitrous oxide and halothane. Bilateral neck incisions
were made. For ECs, bilateral external jugular veins
were removed, inverted, and processed per our previ-
ously reported protocol.11 Briefly, the veins were
sequentially placed into 0.05% trypsin/ethylenedi-
amine tetraacetic acid (EDTA) 0.53 mmol/L (Gibco,
Grand Island, NY) and collagenase 100 units (U)/mL
(Gibco) at 37°C for 10 minutes each. After the veins
were discarded, the trypsin and collagenase solutions
were centrifuged at 1000 revolutions per minute
(rpm) for 10 minutes. The supernatants were discard-
ed, and the cells were suspended in 5 mL of EC
growth media consisting of M-199 (Gibco) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, Utah), FGF-1 5 ng/mL (American Red
Cross, Rockville, Md), bovine lung heparin 5 U/mL
(Pharmacia & Upjohn, Kalamazoo, Mich), 100
U/mL penicillin, and 100 µg streptomycin (Gibco).
The ECs were plated onto a fibronectin (American
Red Cross)–coated T-25 culture flask (2.5 µg/cm2)
and incubated at 37°C in a 5% humidified carbon
dioxide chamber. The EC growth media was changed
every 2 to 3 days, and confluent cells were passaged
using trypsin-EDTA. EC identity was confirmed using
dual staining with Factor VIII (Dako Corp,
Carpenteria, Calif) and α-actin (Sigma Chemical
Company, St Louis, Mo) antibody immunofluores-
cent staining. Only EC cultures exhibiting 95% or
more positive Factor VIII staining and 5% or less pos-
itive α-actin staining were used for the proliferation
assays. ECs were used within passages 1-4.
SMCs were obtained from canine carotid arteries
using a previously published9 explant technique.
Briefly, the carotid arteries were opened longitudi-
nally, and the intima and adventitia were removed by
scraping and dissecting with a scalpel. The medial
layer was minced and placed into SMC growth media
consisting of Dulbecco modified Eagle medium
(DMEM) supplemented with 10% FBS (Hyclone),
10 mmol/L L-nonessential amino acids, 100 U/mL
penicillin, 100 µg/mL streptomycin, 100 mmol/L
L-sodium pyruvate, and 50 µg/mL gentamicin (all
from Gibco unless otherwise stated). Primary SMC
migrating from the explants were used in all experi-
ments. SMC identity was confirmed using immuno-
fluorescent staining with α-actin antibody (Sigma
Chemical Company) and only cultures exhibiting
95% or more positive staining were used in the pro-
liferation assays.
EC and SMC proliferation assays. SMCs,
10,000 cells per well, were plated into 96-well poly-
styrene plastic plates (Becton Dickinson, Lincoln
Park, NJ) in 200 µL of SMC growth media and
allowed to proliferate for 3 days until the wells were
approximately 80% confluent. The media was
removed, the cells were washed with phosphate-
buffered saline (PBS), and 200 µL of serum-free
quiescent media consisting of DMEM:F12 (Gibco),
penicillin/streptomycin (Gibco), insulin 1 µmol/L,
L-ascorbic acid 0.2 mmol/L, and transferrin 5
µg/mL (all from Sigma Chemical Company) were
placed on each well. After 24 hours, 50 µL of FBS
(positive control), PBS (negative control), or test
solutions were placed on the wells. After 48 hours of
the cells being in quiescent media (24 hours after the
addition of cytokines), 1 µCi per well of 3H-thymi-
dine (NEN Life Science Products, Boston, Mass)
was placed on the wells, and the plates were
processed 24 hours later. The media was removed,
and the wells were washed with 0.9% saline to
process. The cells were fixed in 100% methanol
(Fischer Scientific, Fair Lawn, NJ) for 10 minutes
and lysed with distilled water. The DNA was precip-
itated with 5% trichloroacetic acid (Sigma Chemical
Company). The cell lysates were washed with dis-
tilled water, and the DNA was solubilized by adding
100 µL of 0.3 mol/L sodium hydroxide (Sigma
Chemical Company). This solution was placed into
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10 mL of scintillation fluid that contained 20 µL of
acetic acid (Fisher Scientific) to avoid opacification
of the scintillation fluid with an accompanying
dampening of the counts per minute (CPM).
Test solutions (50 µL) were placed on the cells
and contained various amounts of FGF-1, S130K,
and heparin, so that the final concentration in the well
was the stated value. S130K or FGF-1 at 0, 0.1, 10,
or 100 ng/mL with heparin 0, 5, 50, or 500 U/mL
was placed on the SMCs. Each plate contained a col-
umn of wells that received 50 µL of FBS (positive
control). The data were normalized by dividing the
CPM for each well by the average of the positive con-
trol wells on that plate and multiplying by 100% (per-
cent positive control). The variability among the pos-
itive control wells was typically less than 10%. There
were six replicates per plate for each treatment, and
the experiments were performed in duplicate (n = 12
for each observation). The data are expressed as mean
percent positive control ± standard deviation. 
EC assays were performed in an identical fashion
to the SMC assays except that the plates were coat-
ed with fibronectin (American Red Cross) 2.5
µg/cm2. The growth media contained M199, 10%
FBS, and penicillin/streptomycin. The quiescent
media contained Iscove’s Modified Dulbecco’s
Medium (Gibco), penicillin/streptomycin, L-gluta-
mine 2 mmol/L (Gibco), insulin-transferrin-seleni-
um 1x (Gibco), bovine serum albumin 5% (Sigma),
and 2-mercaptoethanol 1x (Gibco). ECs were plat-
ed at 10,000 cells per well and maintained in growth
media for 3 days. Quiescent media was placed on
the cells, and 1 day later test solutions were added
to the wells. 3H-thymidine was added 24 hours after
the test solutions, and the plates were processed in
an identical fashion as in the SMC assays.
FG plate preparation. FG was made by reconsti-
tuting lyophilized human fibrinogen (American Red
Cross) prepared from donor-pooled plasma with 0.9%
saline. For modified FG, heparin and FGF-1 or S130K
were also added to obtain a solution with a final con-
centration of fibrinogen 32 mg/mL, FGF-1 or S130K
0, 1, 10, 100, or 1000 ng/mL, and heparin 0, 5, 
50, or 500 U/mL. Lyophilized human thrombin
(American Red Cross) was reconstituted with 0.9%
saline and added to all solutions to make a final con-
centration of 0.32 U/mL. A solution containing fib-
rinogen and thrombin only was made and used as the
negative control. Before polymerization, the solutions
were pipetted in 30 µL aliquots into 96-well poly-
styrene plastic plates (Becton Dickinson) and allowed
to completely polymerize, about 1 hour, before solu-
tions were placed in the wells that contained FG.
EC and SMC proliferation assays on FG.
Media was placed on the FG for 24 hours and
removed before plating cells to minimize the effect
of soluble FGF-1 and heparin known to be released
from the FG by diffusion. This release is virtually
completed by the first 24 hours.12 Confluent cells
were trypsinized and plated on FG at 5000 cells per
well in 200 µL of media. ECs were plated in media,
which was devoid of FGF-1 and heparin (M199,
10% FBS, penicillin, and streptomycin). SMCs were
plated in SMC growth media (DMEM, 10% FBS, L-
sodium pyruvate, L-nonessential amino acids, peni-
cillin, streptomycin, and gentamicin).
After plating, the cells were allowed to grow for
48 hours, then 3H-thymidine 1 µCi per well was
added, and the plates were processed 24 hours later.
The plates were processed by removing the media
and washing the wells with 0.9% saline. The cells
were fixed in 100% methanol for 10 minutes and
lysed with distilled water. The DNA was precipitat-
ed with 5% trichloroacetic acid. The cell lysates were
washed with distilled water, and the FG was solubi-
lized by adding 100 µL of 0.3 mol/L sodium
hydroxide and heating at 60°C for 35 minutes. This
solution was placed into 10 mL of scintillation fluid
that contained 20 µL of acetic acid to avoid opacifi-
cation of the scintillation fluid with an accompany-
ing dampening of the CPM.
During preliminary experiments, we found that
the FG itself has a very high background that was
unaffected by the composition of the FG and exhibit-
ed very little variance. Therefore, every plate con-
tained wells with FG but no cells, and the average of
these wells was subtracted from the CPM of the test
wells to eliminate the high FG background. Cells plat-
ed on FG with no additives were also placed on each
plate as a negative control, and the data were normal-
ized by dividing the CPM of each well by the average
of the negative control wells and multiplied by 100%.
% of negative control =
[ ]  100%
After the normalization of data for each experi-
ment, the observations from the two experiments
were combined to calculate the mean of the percent
negative control ± standard deviation. All prolifera-
tion experiments were performed in duplicate, and
each treatment had replicates of n = 5 in each exper-
iment (n = 10 for the combined data).
Molecular degradation by thrombin. Purified,
(CPM  BKGave)
negative control ave CPM  BKGave
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recombinant FGF-1 and S130K (20 µg) were resus-
pended in 0.05 mol/L HEPES, 0.25 mol/L sodium
chloride, 5 mmol/L calcium chloride, pH 7.5 (600
µL) in the presence of 6 U of human thrombin. The
samples were incubated at 37°C for the indicated
times. Aliquots (100 µL) were mixed with 20 µL of
6X Laemmlis’ sample buffer. The samples were sub-
jected to polyacrylamide gel electrophoresis in the
presence of sodium dodecylsulfate (SDS/PAGE)
with 15% polyacrylamide gels using reducing condi-
tions. The gels were stained with Coomassie brilliant
blue to visualize intact FGF-1 and thrombin-derived
fragments.
Statistics. Analysis of variance with Fischer’s
Least Square Differences was used as an adjunct test,
and an unpaired Student t test was performed. The
results for these tests were reported as significant at
the P level <.05.
RESULTS
EC and SMC proliferation assays with solu-
ble cytokines. With the cytokines soluble in the
media, similar results were obtained for both EC and
SMC assays. Briefly, S130K induced heparin-inde-
pendent proliferation in both cell lines, whereas in
the absence of heparin, FGF-1 induced only moder-
ate proliferation on SMCs and no significant prolif-
eration on ECs. With the addition of heparin 5
U/mL, the proliferation induced by FGF-1 was dra-
matically increased on both cell lines, and S130K
mitogenic activity was augmented, especially on the
ECs. As the heparin dose increased, proliferation
decreased for both cell lines and with both S130K
and FGF-1. Overall, S130K was more potent, induc-
ing greater proliferation at lower concentrations as
compared with FGF-1. For ECs, maximal prolifera-
tion occurred for both cytokines at concentrations
of 1 ng/mL in the presence of heparin at 5 or 50
U/mL (Table I). For SMCs, maximal proliferation
occurred for S130K at a concentration of 1 ng/mL
with heparin 5 U/mL and FGF-1 at a concentration
of 10 ng/mL with heparin 5 U/mL (Table II). As
the heparin concentration increased to 50 and 500
U/mL, SMC proliferation decreased for both
cytokines. This decrease in proliferation in the pres-
ence of increasing heparin concentration reflects the
known inhibitory effect that heparin displays on
SMC growth.13
EC and SMC proliferation assays on FG.
Once again, the results for both EC and SMC pro-
liferation on FG were similar. Briefly, in the absence
of heparin, S130K induced significant proliferation
at the higher concentrations, whereas FGF-1 within
FG was not significantly different from the negative
controls. Thrombin in the FG degrades FGF-1, and
this finding suggests that the S130K mutation may
protect from thrombin degradation. The addition of
heparin 5 U/mL dramatically increases the prolifer-
ation induced by both cytokines with S130K being
more potent with maximal proliferation occurring at
the 10 ng/mL concentration as compared with the
100 ng/mL concentration of FGF-1 for both cell
lines (Tables III and IV). For ECs, heparin concen-
trations in the FG of 50 U/mL inhibited prolifera-
tion as compared with the heparin 5 U/mL for both
cytokines, and heparin concentrations of 500 U/mL
in the FG caused EC death (data not shown). In
contrast to the ECs, however, heparin concentra-
tions within the FG as high as 500 U/mL had no
effect on SMC proliferation (no significant differ-
Table I. Effect of soluble S130K and FGF-1 with heparin on EC proliferation
Heparin U/mL 0 5 50 500
No cytokine 13 ± 3* 14 ± 2 13 ± 2 3 ± 1*
S130K 0.1 ng/mL 19 ± 7 55 ± 5†‡ 51 ± 7† 8 ± 4
1 20 ± 6 77 ± 7†‡ 78 ± 5† 34 ± 3†
10 22 ± 7† 77 ± 5† 80 ± 5† 58 ± 5†
100 34 ± 8† 73 ± 3† 76 ± 3† 61 ± 3†
FGF-1 0.1 ng/mL 8 ± 1 9 ± 7 14 ± 3 8 ± 6
1 10 ± 2 69 ± 5† 67 ± 3† 37 ± 9†
10 10 ± 1 65 ± 4† 72 ± 5† 52 ± 8†
100 15 ± 1 59 ± 5† 64 ± 6† 51 ± 9†
Media containing 20% serum was used as a positive control on each plate. Data were normalized by dividing the CPM for each well by
the positive control, and the data are shown as mean percent positive control ± standard deviation. N = 12 for each observation.
*P <.001 for PBS versus heparin 500 U/mL.
†P <.001 versus same heparin dose with no cytokine.
‡P <.001 for S130K 0.1 ng/mL versus S130K 1 ng/mL, both with heparin 5 U/mL.
EC, Endothelial cell; FGF-1, fibroblast growth factor 1.
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ences between S130K 10, 100, or 1000 ng/mL
with heparin 5 versus heparin 500 U/mL and FGF-
1 10, 100 or 1000 ng/mL with heparin 5 versus
500 U/mL).
Molecular degradation by thrombin. Incuba-
tion of FGF-1 and S130K with thrombin and subse-
quent analysis with SDS/PAGE revealed that
thrombin degraded both FGF-1 and S130K.
Table II. Effect of soluble S130K and FGF-1 with heparin on SMC proliferation
Heparin U/mL 0 5 50 500
No cytokine 6 ± 1 4 ± 1 2 ± 0 2 ± 0
S130K 0.1 ng/mL 7 ± 1 5 ± 1 2 ± 1 2 ± 0
1 10 ± 1 168 ± 23*† 103 ± 13* 10 ± 2
10 111 ± 18* 158 ± 14* 143 ± 21* 69 ± 10*
100 174 ± 26*‡ 174 ± 18* 131 ± 21* 72 ± 12*
FGF-1 0.1 ng/mL 6 ± 1 3 ± 1 2 ± 0 2 ± 0
1 6 ± 1 31 ± 5*† 8 ± 2 2 ± 0
10 23 ± 3* 146 ± 18* 120 ± 16* 66 ± 12*
100 85 ± 15*‡ 132 ± 13* 113 ± 8* 63 ± 11*
Media containing 20% serum was used as a positive control on each plate. Data were normalized by dividing the CPM for each well by
the positive control, and the data are shown as mean percent positive control ± standard deviation. N = 12 for each observation.
*P <.001 versus same heparin dose with no cytokine.
†P <.001 for S130K 1 ng/mL versus FGF-1 1 ng/mL, both with heparin 5 U/mL. 
‡P <.0001 for S130K 100 ng/mL versus FGF-1 100 ng/mL, both in the absence of heparin.
FGF-1, Fibroblast growth factor 1; SMC, smooth muscle cell.
Table III. Effect of S130K and FGF-1 with heparin contained within FG on EC proliferation
Heparin U/mL 0 5 50
No cytokine 100 ± 12 155 ± 30 139 ± 60
S130K 1 ng/mL 126 ± 17 181 ± 38 141 ± 44
10 125 ± 12 374 ± 100*† 267 ± 100*
100 149 ± 29 395 ± 112* 304 ± 121*
1000 241 ± 38* 382 ± 125* 287 ± 133*
FGF-1 1 ng/mL 124 ± 14 168 ± 40 145 ± 56
10 119 ± 15 249 ± 62*† 161 ± 64
100 123 ± 23 378 ± 112* 248 ± 104*
1000 120 ± 22 375 ± 103* 261 ± 131*
Each plate contained FG with no additives as a negative control, and the data are expressed as mean percent of the negative control ±
standard deviation. N = 10 for each observation.
*P <.01 versus same heparin dose with no cytokine.
†P <.01 for S130K 10 ng/mL versus FGF-1 10 ng/mL, both with heparin 5 U/mL.
EC, Endothelial cell; FG, fibrin glue; FGF-1, fibroblast growth factor 1.
Table IV. Effect of S130K and FGF-1 with heparin contained within FG on SMC proliferation
Heparin U/mL 0 5 50 500
No cytokine 100 ± 11 122 ± 22 97 ± 15 85 ± 18
S130K 1 ng/mL 116 ± 13 196 ± 13* 139 ± 8* 136 ± 30*
10 122 ± 14 331 ± 38*† 280 ± 29* 312 ± 48*
100 138 ± 15* 328 ± 29* 289 ± 29* 335 ± 60*
1000 226 ± 20* 316 ± 29* 292 ± 41* 328 ± 51*
FGF-1 1 ng/mL 123 ± 12 131 ± 21 107 ± 20 96 ± 28
10 118 ± 25 182 ± 13*† 180 ± 19* 182 ± 52*
100 122 ± 14 319 ± 30* 303 ± 36* 331 ± 59*
1000 127 ± 13 321 ± 34* 302 ± 32* 323 ± 58*
Each plate contained FG with no additives as a negative control, and the data are expressed as mean percent of the negative control ±
standard deviation. N = 10 for each observation.
*P <.01 versus same heparin dose with no cytokine.
†P <.001 for S130K 10 ng/mL versus FGF-1 10 ng/mL, both with heparin 5 U/mL.
FG, Fibrin glue; FGF-1, fibroblast growth factor 1; SMC, smooth muscle cell.
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However, there was a relative retardation and
diminution of thrombin-induced degradation with
the S130K, suggesting that the mutation may some-
how protect the molecule (Fig 1). This can be seen
in Fig 1 by the stronger persistence of undegraded
S130K versus FGF-1 at late time points along with
less prominent lower molecular weight bands. This
observation may also explain why S130K in the FG
induced significantly more proliferation than the
negative control in the absence of heparin while
FGF-1 did not. The addition of heparin to the FG
dramatically increased the EC and SMC prolifera-
tion induced by both FGF-1 and S130K, suggesting
that heparin may also protect both molecules from
thrombin inactivation.
DISCUSSION
Site-directed mutagenesis is an important tech-
nique that can alter a molecule by making single or
multiple amino acid substitutions. This allows for
the study of the functions of different regions in a
molecule and, hopefully, the ability to design a more
useful molecule than the parent compound. Our
group has been interested in FGF-1 because of its
relatively strong EC mitogenic and chemoattractant
activity. Unfortunately, FGF-1 also stimulates SMC
proliferation, and this may explain the increased cel-
lular proliferation and capsular thickness observed in
our previously reported canine studies.7,8 In this
paper, we report our results with S130K, a mutant
of FGF-1. Residues 122-137 of human FGF-1 con-
stitute a major heparin-binding domain in the FGF-
1 protein.9 Multiple FGF-1 mutants have been gen-
erated in the laboratory of W. H. Burgess. These
studies have demonstrated that mutations of the
lysines in this region (residues 126, 127, 132) result
in a reduction in the mitogenic potential of the
mutant FGF-1.
Substituting a glutamic acid or glycine for lysine
132 results in as much as a 1000-fold reduction in
mitogenic activity when compared with the wild-
type protein on various cell lines including NIH 3T3
fibroblasts, mouse keratinocytes (BALB-MK), and
human ECs. Interestingly, the mutant retains its
ability to bind to high-affinity cell receptors and to
induce all of the early events associated with FGF-1
stimulation.14,15 The mutant is also as potent as
wild-type FGF-1 in inducing differentiation of
Xenopus species embryos.16 These results establish
the feasibility that site-directed mutagenesis of the
protein can dissect the functions associated with
FGF-1.
We reported previously that amino acids 122-
137 of FGF-1 comprise a major heparin-binding
domain of the protein.9 It is known that the heparin
dependence of FGF-1 mitogenic activity is reduced
Fig 1. Molecular degradation of FGF-1 and S130K by thrombin. FGF-1 and S130K were
incubated with thrombin 6 U for the specified times (x-axis) and then analyzed by
SDS/PAGE. Molecular markers (y-axis) are shown on the left for both gels. FGF-1 and S130K
are 17 kd molecules. Both molecules are susceptible to thrombin degradation, but S130K is
relatively more resistant than FGF-1, as demonstrated by the delayed appearance and dimin-
ished intensity of low molecular weight fragments, suggesting that the mutation offers some
protection from thrombin degradation.
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when cysteine 131 is mutated to a serine residue.17
We have shown that mutation of lysine 132 to a glu-
tamic acid residue reduces the affinity of FGF-1 for
heparin and its mitogenic activity.14 It is unknown
whether this modification affects cysteine-mediated
instability of the protein. More recently we have
begun to mutate nonbasic amino acids in the 122-
137 region of FGF-1 to lysine residues in search of
gain of function mutations. The serine 130 to lysine
mutation described here is the first to exhibit altered
function.
Armed with the knowledge of the importance of
the lysine residues in the heparin-binding region of
FGF-1, we generated S130K, which substitutes a
lysine at the serine 130 position. The S130K mutant
exhibits a threefold increase in mitogenic potency
for BALB-MK cells and a threefold reduction in the
mitogenic activity on NIH 3T3 cells as compared
with wild-type FGF-1. The BALB-MK cell line
demonstrates a greater heparin dependency for wild-
type FGF-1 than the NIH 3T3 cell line. This sug-
gests that heparin-independent mitogenic activity of
the mutants may be predicted according to their
ability to stimulate the BALB-MK cell line (W. H.
Burgess, oral communication, 1998). This appears to
be the case with S130K, in that it induces heparin-
independent proliferation on ECs and SMCs. These
qualities are likely to apply in a positive way to in vivo
models of vascular healing.
With the above information, we decided that
S130K would be an interesting molecule to test on
EC and SMC proliferation studies and that it would
be interesting to study its stimulatory properties
while contained within FG. Soluble S130K and FGF-
1 were tested on ECs and SMCs, and similar results
were obtained for both cell lines. S130K induced
heparin-independent proliferation in both cell lines,
whereas FGF-1 induced moderate proliferation on
SMCs and no significant proliferation on ECs in the
absence of heparin. With the addition of heparin 5
U/mL, the proliferation induced by FGF-1 was dra-
matically increased on both cell lines, and S130K
mitogenic activity was augmented, especially on the
ECs. As the heparin dose increased, proliferation
decreased for both cell lines and with both S130K
and FGF-1. Both molecules appear to induce EC and
SMC proliferation in the presence of heparin, but the
dose-response curve of S130K suggests that is it
more potent, inducing greater proliferation at lower
concentrations as compared with FGF-1.
When the cytokines were contained within FG,
once again, the results for both EC and SMC prolif-
eration on FG were similar. In the absence of heparin,
S130K induced significant proliferation at the higher
concentrations, whereas FGF-1 at any concentration
within FG was not significantly different from the
negative controls. Thrombin in the FG degrades
FGF-1, and this finding suggests that the S130K
mutation may protect from thrombin degradation.
Incubation of FGF-1 and S130K with thrombin and
subsequent analysis by SDS/PAGE revealed that
both molecules are susceptible to thrombin degrada-
tion, but S130K is relatively more resistant to throm-
bin degradation compared with FGF-1. The addition
of heparin 5 U/mL dramatically increases the prolif-
eration induced by both cytokines with S130K being
more potent, with maximal proliferation occurring at
a 10–ng/mL concentration and at the 100–ng/mL
concentration of FGF-1 for both cell lines. The major
difference between ECs and SMCs lies in their
response to heparin in the FG. For ECs, as the
heparin dose increased to 50 U/mL, overall prolifer-
ation decreased for both cytokines. At heparin 500
U/mL, the ECs died. For SMCs, heparin concentra-
tions as high as 500 U/mL did not significantly affect
proliferation as compared with the heparin–5 U/mL
concentration. Earlier reports from our laboratory11
and another laboratory18 have reported that heparin
500 U/mL in FG inhibits SMC proliferation. The
differences in these studies and the current study can
be explained by the release of cytokines and heparin
from the FG within the first 24 hours. These earlier
studies plated cells on FG immediately after the FG
polymerized. In this study, media was placed on the
FG for 24 hours and then removed before plating
cells in new media. Using radiolabeled FGF-1 and
heparin, we have shown that 70% ± 1% of the FGF-1
and 59% ± 2% of the heparin in the FG was released
into the overlying media in the first 24 hours with
minimal release occurring thereafter (66% ± 1% and
67% ± 1% at 96 hours for FGF-1 and heparin, respec-
tively). The cell type or absence of cells did not affect
release, but there was five times more FGF-1 and four
times more heparin in the media at 72 hours for the
immediate versus delayed plating because of diffusive
release in the first 24 hours.12
Thrombin, which is present in FG, stimulates
SMC proliferation. Thus, FG itself can induce SMC
proliferation. Previous studies from our laboratory,
however, show that soluble thrombin concentrations
of 10 U/mL or more are needed to induce SMC pro-
liferation.19 Our FG formulation contains thrombin
concentrations of 0.32 U/mL, and therefore, should
not induce SMC mitogenesis.
Ultimately, the goal of this research is to find an
FG mixture that will enhance endothelialization of
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prosthetic grafts and angioplasty sites without caus-
ing intimal hyperplasia from SMC proliferation.
Although S130K is an interesting molecule with
many potential uses, it does not appear to be a good
candidate for our canine in vivo studies because of its
proliferative effect on SMCs. Using site-directed
mutagenesis to alter cytokine function is an exciting
avenue of research. With S130K, we are currently
exploring its angiogenic potential, and we will also
continue to screen new FGF-1 mutants. These tech-
niques should allow the delivery of mutant growth
factors to areas of vascular intervention to induce
specific, desired responses. We believe that these
studies will enhance our knowledge of the function
of various regions of the FGF-1 molecule, allowing
us to more precisely design increasingly more useful
FGF-1 mutants.
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